Skye and Redx form new entity with $125M to advance fibrosis assets
Skye Bioscience and Redx Pharma have combined in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.
Skye Bioscience
NASDAQ: SKYE $0.28 USD
Clinical-stage biopharmaceutical company developing peripheral CB1 receptor therapies for obesity and metabolic conditions. Recently combined with Redx Pharma into Fibrx Therapeutics to advance a fibrosis-focused pipeline.
Company Info
Sector:Metabolic Disease / Cannabinoid Therapeutics
Headquarters:San Diego, CA, USA
Founded:2011
Website:skyebioscience.com/
Upcoming Milestones & Key Dates
2026 H2
Clinical readout
Phase 2 nimacimab topline data
Clinical Development Pipeline
Nimacimab (SBI-100)
Target: Peripheral CB1 receptor antibodyCB1 Receptor Inhibitor
Target: CB1 receptorRecent News
Leadership Team
Punit Dhillon
President & Chief Executive Officer
Paul Grayson
Chairman of the Board
Karen Smith
Chief Medical Officer